Amneal Pharmaceuticals (NYSE:AMRX) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.90-1.00 for the period, compared to the Thomson Reuters consensus estimate of $1.02.

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Amneal Pharmaceuticals in a research note on Friday, May 18th. They set a neutral rating and a $18.00 target price for the company. ValuEngine upgraded shares of Amneal Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, August 3rd. Morgan Stanley assumed coverage on shares of Amneal Pharmaceuticals in a research note on Monday, July 23rd. They set an overweight rating and a $22.00 target price for the company. Zacks Investment Research downgraded shares of Amneal Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 17th. Finally, B. Riley assumed coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 22nd. They set a buy rating and a $26.00 target price for the company. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $23.67.

NYSE AMRX opened at $20.30 on Friday. The company has a debt-to-equity ratio of 12.94, a current ratio of 1.64 and a quick ratio of 1.19. Amneal Pharmaceuticals has a 1 year low of $13.47 and a 1 year high of $25.70. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 32.22, a P/E/G ratio of 0.95 and a beta of 1.28.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings data on Thursday, August 9th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Amneal Pharmaceuticals had a negative net margin of 68.39% and a negative return on equity of 29.81%. The company had revenue of $462.33 million during the quarter, compared to the consensus estimate of $460.82 million. The business’s quarterly revenue was down 2.5% compared to the same quarter last year. sell-side analysts anticipate that Amneal Pharmaceuticals will post 1.01 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Read More: Stock Symbols Definition, Examples, Lookup

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.